SCHEMBL20004013

SCHEMBL20004013

COc1ccnc(Nc2cccc(F)c2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 3/20 0.56
PIK3CA P42336 2/20 0.56
CDK2 P24941 2/20 0.54
CDK4 P11802 1/20 0.54
EGFR P00533 1/20 0.53
CDK5 Q00535 2/20 0.49
DAPK3 O43293 1/20 0.49
JAK2 O60674 1/20 0.49
PRKD3 O94806 1/20 0.49
PIM1 P11309 1/20 0.49
PRKACA P17612 1/20 0.49
FLT3 P36888 1/20 0.49
MAPK8 P45983 1/20 0.49
CSNK1A1 P48729 1/20 0.49
CDK8 P49336 1/20 0.49
CLK2 P49760 1/20 0.49
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
CDK9 P50750 1/20 0.49
RPS6KA3 P51812 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27114966 0.86 PIK3CA (0.49) PIK3CGPIK3CACDK2CDK4EGFR
SCHEMBL27114963 0.84 EGFR (0.63) PIK3CGPIK3CACDK2CDK4EGFR
SCHEMBL27116528 0.83 PIK3CG (0.64) PIK3CGPIK3CACDK2CDK4CDK5
SCHEMBL27116179 0.82 PIK3CG (0.66) PIK3CGPIK3CACDK2CDK4EGFR
SCHEMBL2280151 0.82 AURKA (0.59) CDK2CDK4EGFRJAK2PIM1
SCHEMBL27114723 0.81 EGFR (0.62) PIK3CGPIK3CACDK2EGFRCDK5
SCHEMBL91451 0.81 SMN1; SMN2 (0.67) PIK3CGPIK3CACDK2CDK4CDK5
SCHEMBL4736185 0.79 PIK3CG (0.80) PIK3CGPIK3CACDK2CDK4EGFR
SCHEMBL27115897 0.79 PIK3CG (0.69) PIK3CGPIK3CACDK2CDK4EGFR
SCHEMBL13950752 0.79 TP53 (0.51) EGFRPOLBTP53MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 US disclosed
EP-3277677-B9 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-07-14 EP disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 US disclosed
EP-3277677-B1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-02-24 EP disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 US disclosed
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-06-11 US disclosed
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-10-24 US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PIK3CG 3247/4885PIK3CA 3397/4885CDK2 1321/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PIK3CG 2273/4885PIK3CA 2723/4885CDK2 1711/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PIK3CG 2273/4885PIK3CA 2723/4885CDK2 1711/4885
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PIK3CG 2219/4885PIK3CA 2649/4885CDK2 1956/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PIK3CG 3247/4885PIK3CA 3397/4885CDK2 1321/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PIK3CG 2273/4885PIK3CA 2723/4885CDK2 1711/4885
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PIK3CG 2273/4885PIK3CA 2723/4885CDK2 1711/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PIK3CG 2273/4885PIK3CA 2723/4885CDK2 1711/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PIK3CG 2273/4885PIK3CA 2723/4885CDK2 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.